阿根廷COVID-19有创通气患者临床特征与结局:SATICOVID前瞻性多中心队列研究
年龄、Charlson评分、ICU外插管、升压药使用、D-二聚体、PaO2/FiO2、动脉pH、驱动压、急性肾损伤和入院月份为独立死亡预测因素。
要点
- 年龄、Charlson评分、ICU外插管、升压药使用、D-二聚体、PaO2/FiO2、驱动压、急性肾损伤等为独立死亡预测因素。
核心结论
- 在需要有创机械通气的COVID-19患者中,肺保护性通气虽广泛应用,但死亡率仍很高。
- 本研究的死亡预测因素与高收入国家有创通气患者研究中的发现大致一致。
研究设计与样本
- 前瞻性、多中心队列研究(SATICOVID),纳入阿根廷63个ICU中18岁及以上、RT-PCR确诊COVID-19且接受有创机械通气的患者。
- 主要结局为全因院内死亡,次要结局包括ICU死亡、死亡独立预测因素、有创机械通气时长及生理呼吸和机械通气变量变化模式。
- 研究注册号ClinicalTrials.gov NCT04611269,已完成。
临床怎么用
- 对于有创通气的COVID-19患者,应关注年龄、Charlson评分、插管地点、升压药使用、D-二聚体、PaO2/FiO2、动脉pH、驱动压和急性肾损伤等预后因素。
- 肺保护性通气策略虽已普遍应用,但需注意驱动压等通气参数与死亡风险相关,优化通气管理可能改善结局。
- 本研究提示中等收入国家ICU中COVID-19有创通气患者死亡负担重,医疗资源紧张可能影响结局,需针对可改善环节加强管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although COVID-19 has greatly affected many low-income and middle-income countries, detailed information about patients admitted to the intensive care unit (ICU) is still scarce. Our aim was to examine ventilation characteristics and outcomes in invasively ventilated patients with COVID-19 in Argentina, an upper middle-income country. METHODS: In this prospective, multicentre cohort study (SATICOVID), we enrolled patients aged 18 years or older with RT-PCR-confirmed COVID-19 who were on invasive mechanical ventilation and admitted to one of 63 ICUs in Argentina. Patient demographics and clinical, laboratory, and general management variables were collected on day 1 (ICU admission); physiological respiratory and ventilation variables were collected on days 1, 3, and 7. The primary outcome was all-cause in-hospital mortality. All patients were followed until death in hospital or hospital discharge, whichever occurred first. Secondary outcomes were ICU mortality, identification of independent predictors of mortality, duration of invasive mechanical ventilation, and patterns of change in physiological respiratory and mechanical ventilation variables. The study is registered with ClinicalTrials.gov, NCT04611269, and is complete. FINDINGS: Between March 20, 2020, and Oct 31, 2020, we enrolled 1909 invasively ventilated patients with COVID-19, with a median age of 62 years [IQR 52-70]. 1294 (67·8%) were men, hypertension and obesity were the main comorbidities, and 939 (49·2%) patients required vasopressors. Lung-protective ventilation was widely used and median duration of ventilation was 13 days (IQR 7-22). Median tidal volume was 6·1 mL/kg predicted bodyweight (IQR 6·0-7·0) on day 1, and the value increased significantly up to day 7; positive end-expiratory pressure was 10 cm H2O (8-12) on day 1, with a slight but significant decrease to day 7. Ratio of partial pressure of arterial oxygen (PaO2) to fractional inspired oxygen (FiO2) was 160 (IQR 111-218), respiratory system compliance 36 mL/cm H2O (29-44), driving pressure 12 cm H2O (10-14), and FiO2 0·60 (0·45-0·80) on day 1. Acute respiratory distress syndrome developed in 1672 (87·6%) of patients; 1176 (61·6%) received prone positioning. In-hospital mortality was 57·7% (1101/1909 patients) and ICU mortality was 57·0% (1088/1909 patients); 462 (43·8%) patients died of refractory hypoxaemia, frequently overlapping with septic shock (n=174). Cox regression identified age (hazard ratio 1·02 [95% CI 1·01-1·03]), Charlson score (1·16 [1·11-1·23]), endotracheal intubation outside of the ICU (ie, before ICU admission; 1·37 [1·10-1·71]), vasopressor use on day 1 (1·29 [1·07-1·55]), D-dimer concentration (1·02 [1·01-1·03]), PaO2/FiO2 on day 1 (0·998 [0·997-0·999]), arterial pH on day 1 (1·01 [1·00-1·01]), driving pressure on day 1 (1·05 [1·03-1·08]), acute kidney injury (1·66 [1·36-2·03]), and month of admission (1·10 [1·03-1·18]) as independent predictors of mortality. INTERPRETATION: In patients with COVID-19 who required invasive mechanical ventilation, lung-protective ventilation was widely used but mortality was high. Predictors of mortality in our study broadly agreed with those identified in studies of invasively ventilated patients in high-income countries. The sustained burden of COVID-19 on scarce health-care personnel might have contributed to high mortality over the course of our study in Argentina. These data might help to identify points for improvement in the management of patients in middle-income countries and elsewhere. FUNDING: None. TRANSLATION: For the Spanish translation of the Summary see Supplementary Materials section.
引用
- Estenssoro E, Loudet CI, Ríos FG, et al. Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study. Lancet Respir Med. 2021. PMID: 34224674. doi:10.1016/S2213-2600(21)00229-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。